AA
NAGE

ALPS Advisors’s Niagen Bioscience NAGE Stock Holding History

ALPS Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-47,978
Closed -$305K – 1162
2025
Q4 		$305K Buy
47,978
+528
+1% +$3.67K ﹤0.01% 938
2025
Q3 		$443K Buy
+47,450
New +$479K ﹤0.01% 829

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ALPS Advisors's NAGE Position: Q1 2026 in Review

ALPS Advisors sold out of Niagen Bioscience (NAGE) in Q1 2026, closing a stake of 47,978 shares — an estimated $305K sold.

ALPS Advisors first reported a position in NAGE in Q3 2025 and held it in 2 quarters. The position peaked at $443K in Q3 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

  • ALPS Advisors reported no remaining Niagen Bioscience position as of Q1 2026 after selling out during the quarter.
  • ALPS Advisors sold 47,978 Niagen Bioscience shares in Q1 2026, an estimated $305K.
  • ALPS Advisors first reported a position in Niagen Bioscience in Q3 2025 and held it in 2 quarters.
  • ALPS Advisors's Niagen Bioscience position peaked at $443K in Q3 2025.
  • 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.